GAMMA Investing LLC Has $600,000 Stock Holdings in DexCom, Inc. $DXCM

GAMMA Investing LLC cut its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 6.1% in the second quarter, Holdings Channel reports. The firm owned 6,874 shares of the medical device company’s stock after selling 444 shares during the period. GAMMA Investing LLC’s holdings in DexCom were worth $600,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its position in DexCom by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company’s stock worth $3,240,763,000 after buying an additional 925,882 shares during the period. Jennison Associates LLC increased its position in DexCom by 37.7% in the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock worth $718,632,000 after buying an additional 2,879,489 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in DexCom by 22.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after buying an additional 1,868,241 shares during the period. Nuveen LLC bought a new position in DexCom in the 1st quarter worth approximately $554,893,000. Finally, Raymond James Financial Inc. increased its position in DexCom by 21.8% in the 1st quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company’s stock worth $229,117,000 after buying an additional 601,088 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the company’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director directly owned 51,121 shares in the company, valued at $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 500 shares of the company’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares in the company, valued at $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,849 shares of company stock valued at $564,733. 0.32% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on DXCM shares. Barclays lifted their price target on DexCom from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 30th. Piper Sandler lifted their price target on DexCom from $90.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, July 31st. Mizuho lifted their price target on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 16th. William Blair raised DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Finally, Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 10th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $99.89.

DexCom Stock Performance

DXCM opened at $67.50 on Thursday. The stock has a market cap of $26.47 billion, a PE ratio of 46.88, a P/E/G ratio of 1.43 and a beta of 1.48. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25. The stock’s 50 day simple moving average is $78.92 and its 200-day simple moving average is $78.05.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.DexCom’s quarterly revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. Sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.